We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genotoxic Genes in Certain Gut Bacteria Linked to Chronic Bowel Inflammation and Colon Cancer

By LabMedica International staff writers
Posted on 29 Aug 2012
Certain strains of gut bacteria - Escherichia coli bearing the polyketide synthase (pks) cluster of genotoxic genes – have been linked to chronic inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and to the development of colorectal cancer (CRC).

Polyketide synthases are a family of multidomain enzymes or enzyme complexes that produce polyketides, a large class of secondary metabolites in bacteria, fungi, plants, and a few animal lineages. More...
Polyketide synthase products include lipids with antibiotic, antifungal, antitumor, and predator-defense properties. They are an important source of naturally occurring small molecules used for chemotherapy. For example, many of the commonly used antibiotics, such as tetracyclin, and macrolides are produced by polyketide synthases. Other industrially important polyketides are rapamycin (immunosuppressant), erythromycin (antibiotic), lovastatin (anticholesterol drug), and epothilone B (anticancer drug).

Investigators at the University of Liverpool (United Kingdom) and colleagues in the USA and Canada used high-throughput sequencing to reveal that inflammation modified gut microbial composition in colitis-susceptible interleukin-10–deficient (Il10−/−) mice. Monocolonization with the commensal Escherichia coli strain NC101 promoted invasive carcinoma in azoxymethane (AOM)–treated Il10−/− mice. Furthermore, mucosa-associated pks+ E. coli were found in a significantly high percentage of human inflammatory bowel disease and CRC patients.

Other results published in the August 16, 2012, online edition of the journal Science revealed that deletion of the polyketide synthase (pks) genotoxic island from E. coli NC101 decreased tumor multiplicity and invasion in AOM/Il10−/− mice, without altering intestinal inflammation.

Contributing author Dr. Jonathan Rhodes, professor of medicine at the University of Liverpool, said, "The fact that the pks-positive E. coli seemed to promote colon cancer in mice without causing increased inflammation led us to investigate its possible role in human colon cancer. The marked increase in the presence of these bacteria in the colon, not only in patients with inflammatory bowel disease, but also in patients with colon cancer who do not have inflammatory bowel disease, suggests that damage caused to DNA, as a result of the toxin that the pks genes produce, may promote the development of colon cancer."

Related Links:

University of Liverpool



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.